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Tumour lysis syndrome is a catastrophic complicalion of treatment of certain neoplasms. It is usually
seen with the tumours that have high growth fractions, increased bulk and extreme sensitivity to
cytotoxic therapy. Most commonly it occurs in association with hematologic malignancies such as
lymphomas and leukaemias. Rarely it has been observed with solid tumours like small cell lung cancer,
seminoma and carcinoma of the breast. The syndrome develops due to massive cell lysis occurring
within a few hours to a few days of starting the cytotoxic therapy. It is characterized by hyperuricemia,
hyperkalemia, hyperphosphatemia and hypocalcaemia. Acute renal failure, cardiac arrhythmias and
sudden death may occur. Tumour lysis syndrome has hitherto not been reported as a complicalion of
radiotherapy only. We recently observed a patient with a diagnosis of chronic myeloid leukaemia who
received splenic irradiation for massive splenomegaly and developed full-blown tumour lysis
syndrome. Pathogenesis and clinical implications are discussed.
CASE REPORT 
A 38 years old male was admitted to The Aga Khan University Hospital with three days history of
vomiting, dysuria, haematuria and oliguria. He was also complaining of LUQ pain. Patient had history
of LUQ pain and fever since November, 1990. He was found to have massive splenomegaly. A blood
count done at that time showed hemoglobin 8.6 g/dl, WBC 257,000/cmm with 40% neutrophils, 9%
lymphocytes, 3% eosinophils, 3% basophils, 17% metamyelocytes, 27% myelocytes and 1% blasts. He
also had some nucleated red cells in the peripheral blood. A diagnosis of chronic myeloid leukaemia
was made. Due to massive splenomegaly, he received splenic irradiation. He did well for three months
but in early March he developed LUQ pain again, as well as fever and splenomegaly. His hemogram
revealed hemoglobin of 11.3 g/dl, WBC 216,000/cmm with 10% neutrophils, 52% lymphocytes, 2%
metamyelocytes, 4% myelocytes and 30% blasts. His platelet count was 45,000. He was re-started on
splenic irradiation. lie received radiotherapy for five days. No other treatment was given. In the next
three days he developed severe nausea and vomiting. He also developed dysuria, haematuria and later
on oliguria. With these complaints he was admitted to this hospital for the first time on March 14, 1991.
lIe was afebrile but very sick looking young man in considerable distress. He had generalized
lymphadenopathy. His spleen was enlarged upto the umbilicus. His CBC revealed hemoglobin of 6.1
g/dl, WBC 2,300/cmm with 10% neutrophils, 72% lymphocytes and 18% blasts. His platelet count was
9,000. His electrolytes and blood chemistries revealed sodium 133 mEq/L, potassium 8.3 mEq/L
bicarbonate 9.2 mEq/L calcium 5.9 mg/dl, phosphorus 31.5 mg/dl, BUN 108 and creatinine 5.0 mg/dl.
Serum uric acid was 50 mg/dl. His ECG revealed tented T waves. Bone marrow examination, reported
later, confirmed infiltration with blasts. A diagnosis of CML in blast crisis and acute tumour lysis
syhdrome was made. He was treated with emergency measures to lower serum potassium with calcium
gluconate, insulin and glucose and kayexalate. He was hydrated and forced alkaline diuresis was
initiated. He received allopurinol for hyperuricemia and aludrox for hyperphosphatemia. His serial
electrolytes and other metabolic changes are shown in Figure.
With these aggressive measures, he survived the tumour lysis syndrome. On normalization of his
metabolic abnormalities he was started on antilcukaemia therapy.
DISCUSSION 
Certain malignancies, particularly those with high tumour burden and growth fractions may respond
dramatically to cytotoxic therapy resulting in the tumour lysis syndrome1. Most often it is seen with
tumours that are exquisitely sensitive to treatment such as lymphomas and leukaemia2-7. Infrequently it
has been observed during the treatment of certain solid tumours such as small cell carcinoma of lung,
breast cancer or seminoma8-10. The syndrome develops due to massive release of products of cell
destruction, i.e., uric acid, potassium and phosphate into the circulation. The risk of developing this
syndrome is increased in patients with high tumour bulk, high LDH, presence ofhyperuricemia prior to
the initiation of therapy, extreme leukocytosis and pre-existing renal impairment. Our patient had a
very high tumour burden as reflected by extremely high leucocyte count. Presence of other factors
remains unknown since patient had previously been treated elsewhere. Tumour lysis syndrome,
however, is most commonly observed after the institution of chemotherapy. Even small doses of
cytotoxic drugs such as given for intrathecal therapy, may precipitate tumour lysis syndrome in an
exquisitely chemosensitive cancer11. Only rarely hawk been precipitated by other agents, ag., steroid,
tamoxifen and alpha interferon9,12-15. Our patient developed this complication after splenic irradiation.
This is most unusual and hitherto unreported complication of this therapy. However, development of
tumour lysis syndrome in this patient can easily be explained by extremely high white cell count, high
growth fraction of leukaemic cells, massive splenomegaly, increased blood supply of an enlarged
spleen that would have exposed very high number of blood cell to the destructive effect of radiation
and exquisite radiosensitivity of myeloid and lymphoid cells. There are many complications that follow
the development of this syndrome. Hyperuricemia can cause acute renal failure. This is due to the
precipitation of urates in the collecting tubules. Hyperphosphatemia can cause hypocalcaemia due to
the sequestration of calcium in the bones. If the product of calcium and phosphate exceeds 70, these
may precipitate in different organs resulting in organ dysfunction. lf it happens in the kidney, acute
renal failure may ensue. Severe hyperkalemia may lead to cardiac arrhythmias and sudden death.
Metabolic acidosis may be caused by hyperuricemia, acute renal failure or lactic acidosis. Death may
be the result of acute renal failure or arrhythmias. The best management of this syndrome is by
prevention. Delaying the cytotoxic therapy, until the pre-existing metabolic derangements have been
corrected, may decrease the chances of developing tumour lysis syndrome. This could be achieved by
intravenous hydration, usage of allopurinol to control hyperuricemia, alkalinization of urine with
sodium bicarbonate and maintenance of good urinary output may be helpful. flowever, at times, this
complication may develop in spite of all these measures. The treatment of the syndrome, once
established, is extremely difficult16. The usual measures include correction of hyperkalemia with
dextrose and insulin, sodium bicarbonate infusions for metabolic acidosis, intravenous calcium to
correct hypocalcaemia and aluminum hydroxide to decrease hyperphosphatemia. Hemodialysis may be
indicated if potassium is over 6 mEqJL, uric acid over 10 mg/dl, serum creatinine over 10 mg/dl,
phosphate above 10 mg/dl, volume overload or symptomatic hypocalcemia5. In spite of these measures
mortality may be high. In conclusion, we described a case of full blown tumour lysis syndrome that
occurred as a complication of splenic irradiation in a patient with chronic leukaemia who had
undergone blast transformation. With aggressive management, the patient survived the consequences of
severe metabolic derangement.
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